John Doyle

John J. Doyle, Dr.P.H., M.P.H.

Group Vice President, Principal Scientist
Health Sciences
New York
  • CV (English)
  • Contact Card
  • LinkedIn

Dr. Doyle is an epidemiologist and health services researcher who specializes in studying the risks, benefits, and value of healthcare interventions. He has over 25 years of experience in conducting research covering specialties such as pharmacoepidemiology, health economics & outcomes research, and real-world evidence. He has applied these disciplines to develop novel models of market access for biopharmaceuticals, including outcomes-based agreements and innovative financing to support value-based healthcare initiatives. Dr. Doyle has published over 200 abstracts and peer-reviewed articles, with special concentration in oncology. He serves as the co-chair of the Health Economic Impact Steering Committee for the Alliance for Regenerative Medicine where he focuses on the value assessment of cell and gene therapy. Dr. Doyle frequently gives presentations and lectures on the above areas of expertise in both commercial and academic settings internationally. Dr. Doyle has served on the faculty at Columbia University’s Mailman School of Public Health since 2005.

CREDENTIALS & PROFESSIONAL HONORS

  • Dr.P.H., Epidemiology, Columbia University, 2005
  • M.P.H., Epidemiology, Columbia University, 1998
  • B.Sc., Business Management and Applied Economics, Cornell University, 1992
  • Dissertation Defended with Distinction, Columbia University Mailman School of Public Health

Publications

Peer-reviewed Articles

Doyle JJ, Hawryluk H, Niemira J, Wood B. Evidence-Based Valuation in Oncology: Lessons Learned from a Case Study. Therapeutic Innovation & Regulatory Science, Official Journal of DIA. July 2018.

Halim, ND, Doyle, JJ. Public Health Innovation: Biopharmaceuticals Lost in Translation? Therapeutic Innovation & Regulatory Science, Official Journal of DIA. Volume 47. Number 3. May 2013.

Doyle, JJ, Edlin, M. Drug Manufacturers Seek Payer Feedback. Managed Healthcare Executive. March 6, 2013.

Doyle JJ, Horowicz-Mehler N. How the Biopharmaceutical Industry Can Navigate a Healthcare Ecosystem Increasingly Driven by Demands for Comparative Effectiveness Research (CER). Pharmaceutical Medicine. Dec 2011. 25 (6): 361-365. Doi: 10.2165/11594530.

Doyle, JJ. The Effect of Comparative Effectiveness Research on Drug Development Innovation: a 360° Value Appraisal. Dove Press. March 2011. 2011:1:27-34. DOI: 10.2147/CER.S15478

Doyle, JJ. Commentary: The Real-world Convergence of Comparative Effectiveness Research and Risk-Benefit Assessment. Drug Information Journal. 2011. 45: 691-696. Doi: 0092-8615/2011

Shorr AF, Doyle JJ, Stern LS, Dolgitser M, Zilberberg MD. Anemia in chronic abstructive pulmonary disease; epidemiology and economic implications. Current Medical Research And Opinion 2008;24(4):1123-30.

Zilberg M, Stern L, Wiederkehr D, Doyle JJ, Shorr A. Anemia, Transfusions and Hospital Outcomes among Critically Ill Patients on Prolonged Acute Mechanical Ventilation: A Retrospective Cohort Study. Crit Care. 2008; 12 (2):R60. Published online 2008 April 28. Doi: 10:1186/cc6885. PMCID: PMC2447616

Doyle JJ, Stern L, Hagan M, Hao J, Gricar J. Advances in Contraception: IUDs from a Managed Care Perspective. Journal of Women’s Health. July 2008, 17 (6): 987-992.

Walt JG, Chiang TH, Stern LS, Doyle JJ. Characterization of the Living Environments of End-Stage Glaucoma Patients and Use of Low-Vision Care Services: A Physician Survey Study. Visual Impairment Research. 2007: 9:23-31.

Doyle JJ, Neugut AI, Jacobson JS, Wang J, McBride R, Grann A, Grann VR, Hershman D. Radiation Therapy, Cardiac Risk Factors, and Cardiac Toxicity in Early-Stage Breast Cancer Patients. International Journal of Radiation Oncology, Biology, Physics. 2007: 68:82-93.

Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT, Dua HS, Hom M, Karpecki PM, Laibson PR, Lemp MA, Meisler DM, Del Castillo JM, O’Brien TP, Pflugfelder SC, Rolando M, Schein OD, Seitz B, Tseng SC, van Setten G, Wilson SE, Yiu SC. Dysfunctional Tear Syndrome: A Delphi approach to treatment recommendations. Cornea. 2007 Aug; 26(7):901

Kaunitz AM, Stern LS, Doyle JJ, Etschmaier MR. Use of Levonorgestrel-IUD in the treatment of Menorrhagia: Improving patient outcomes while reducing the need for surgical management. Managed Care Interface. 2007: 20: 47-50.

Bukstein DA, Murphy KR, Katz LM, Ramachandran S, Doyle JJ, Stern LS. Outcomes Among a Young Population of Pediatric Asthma patients Using Controller Therapies: Results from a Retrospective Database Analysis. Pediatric Asthma, Allergy & Immunology 2007;20(4):211-21.

Katz LM, Howell JB, Doyle JJ, Stern LS, Rosenblatt LC, Piech CT, Zilberberg MD. Outcomes and charges of elderly patients with acute myeloid leukemia. American Journal of Hematology. 2006: 81: 850-857.

Stern L, Berman J, Lumry W, Katz L, Wang L, Rosenblatt L, Doyle JJ. Medication compliance and disease exacerbation in patients with asthma: a retrospective study of managed care data. Annals of Allergy, Asthma & Immunology. 2006: 97: 402-408.

Marcus P, Oppenheimer EA, Patel PA., Katz LM, Doyle JJ. Use of nebulized inhaled corticosteroids among older adult patients: an assessment of outcomes. Annals of Allergy, Asthma & Immunology. 2006: 96: 763-743.

Buchholz P, Steeds CS, Stern LS, Wiederkehr DP, Doyle JJ, Katz LM, Figueiredo FC. Using utility assessment to measure the impact of dry eye disease. Ocular Surface. 2006: 4(3): 155-161.

Lee PP, Walt JG, Doyle JJ, Kotak SV, Evans SJ, Burdenz DL, Chen PP, Coleman AL, Feldman RM, Jampel HD, Katz LJ, Mills RP, MD, Myers JS, Noecker RJ, Piltz-Seymour JR, Ritch RR, Schacknow PN, Serle JB, Trick GL. A multicenter, Retrospective Pilot Study of Resource Use and Costs Associated With Severity of Disease in Glaucoma. Archives of Ophthalmology. 2006; 124 (1): 12-19.

Traverso CE, Walt JG, Kelly SP, Hommer AH, Bron AM, Denis P, Nordmann JP, Renard JP, Bayer A, Grehn F, Pfeiffer N, Cedrone C, Gandolfi S, Orzalesi S, Nucci C, Rossetti L, Azuara-Blanco A, Bagnis A, Hitchings R, Salmon JF, Bricola G, Buchholz PM, Kotak SV, Katz LM, Siegartel LR, Doyle JJ. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilization in Europe. Br J Opthalmol. 2005; 89 (10): 1245-1249.

Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman D. Chemotherapy and cardiotoxicity in breast cancer patients 65 years and older: A Population-based Study. Journal of Clinical Oncology 2005; 23 (34); 597-605.

Stuart Montgomery, JJ Doyle, Lee Stern, and Christopher R. McBurney. Economic Considerations in the Prescribing of Third Generation Antidepressants. Pharmacoeconomics 2005; 23 (5); 477-491

Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: Findings from a retrospective analysis of Health plan data. J Urol. 2004;171(6):2250-2254.

Casciano J, Amaya K, Doyle JJ, Arikian S, Shear N, Haspel M, Kahler K. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. Manag Care. 2003;12(3):47-54.

Buller N, Gillen D, Casciano R, Doyle JJ, Wilson K. A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom. Pharmacoeconomics. 2003;21 (1):25-32.

Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110 (7):1412-1419.

Thaulow E, Jorgensen B, Doyle JJ, Casciano R, Casciano J, Kopp Z, Arikian S, Kim R. A pharmacoeconomic evaluation of results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES) in Norway and Canada. Int J Cardiol. 2002;84(1):23-30; discussion 30-32.

Serle J, Cantor L, Gross R, Katz J, Mundorf T, Noecker R, Severin T, Simmons S, Walt J, Casciano J, Evans S, Doyle JJ. Best practice treatment algorithm for primary open-angle glaucoma: implications for US ophthalmology practice. Manage Care Interface. 2002;15(7):37-48.

Flack JM, Casciano R, Casciano J, Doyle JJ, Arikian S, Tang S, Arocho R. Cardiovascular disease costs associated with uncontrolled hypertension. Manage Care Interface. 2002;15(11):28-36.

Doyle JJ, Thaulow E, Jorgensen B, Casciano R, Casciano J, Kopp Z, Marchant N. Amlodipine treatment in patients undergoing PTCA in the UK: a cost-effectiveness analysis. British Journal of Cardiology. 2002;9(1):31-36.

Doyle JJ, McGuire A, Arocho R. A pharmacoeconomic evaluation of results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES) in Norway and Canada. International Journal of Cardiology. 2002;84:23-30; discussion 30-2.

Doyle JJ, McGuire A, Arocho R, Arikian S, Casciano J, Svangren P, Casciano R, Kim R, Kugel H. A cost-effectiveness evaluation of amlodipine usage in patients with coronary artery disease in Sweden. Int J Clin Pract. 2002;56(2):76-81.

Doyle JJ. Developing glaucoma treatment recommendations. Supplement to Ophthalmology Management. 2002.

Casciano R, Doyle JJ, McGuire A. , Arocho R, Arikian S, Casciano J, Kugel H, Marchant N, Kim R. The cost-effectiveness of Amlodipine treatment in patients with coronary Artery Disease in the U.K. British Journal of Cardiology. 2002;9(2).

Casciano, R, Doyle JJ, Chen, J, Arikian, S, Casciano, J, Kugel, H, Arocho, R. Economic Benefits of Amlodipine Treatment in Patients with Coronary Artery Disease. Pharmacoeconomics. 2002; 20(8):553-563.

Thaulow E, Jorgensen B, Doyle JJ, Casciano R, Casciano J, Arikian S, Kim R, Arocho R, Kopp Z. A pharmacoeconomic evaluation of amlodipine usage in patients undergoing PTCA in the US using results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES). J Cardiovasc Manag. 2001;12(2):31-3

Doyle JJ, Casciano J, Arikian S, Tarride JE, Gonzalez MA, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): A comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health. 2001; 4(1):16-31.

Doyle JJ, Omvik P, Arikian S, Casciano J, Casciano R, Gonzalez M. A, Arocho R. A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension. Manag Care Interface. 2001;14(3):82-7.

Casciano J, Doyle JJ, Arikian S, Casciano R. The health economic impact of antidepressant usage from a payer's perspective: A multinational study. Int J Clin Pract. 2001;55(5):292-9.

Casciano J, Doyle JJ, Casciano, R, Kopp, Z, Marchant, N, Bustacchini, S, Arikian, S, Kim, R. The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy. Int J Clin Pract. 2001;55(2):84-92.

Doyle JJ, Casciano J, Arikian SR, Tarride JE, Gonzalez M, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): A comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value in Health, 2001; 4 (1):1-16.

Casciano J, Arikian SR, Doyle JJ, Casciano R. A managed care validation program for a pharmacoeconomic model of major depression. Value in Health, 2000; 3 (2): 80

Doyle JJ, Arikian SR, Casciano J, Casciano R, Baleva J, Gonzalez M. A pharmacoeconomic evaluation of hormone replacement therapy in the United Kingdom and Belgium. Value in Health, 2000; 3 (2): 100.

Arikian SR, Ciuryla V, Doyle JJ, Casciano J, Casciano R, Hvidsten K. A multinational pharmacoeconomic evaluation of the seven-valent pneumococcal conjugate vaccine. Value in Health, 2000; 3 (2): 121-122.

Casciano R, Arikian S, Tarride J-E, Casciano J, Doyle JJ. Antidepressant selection for major depressive disorder: the budgetary impact on managed care. Drug Benefit Trends. 2000.

Flack J.M, Doyle JJ, Casciano R, Arocho R, Casciano J, Gonzalez M. The health economic impact of failure to reach blood pressure goals. The American Journal of Hypertension, 2000; 13: 17A-19A.

Arikian SR, Casciano J, Doyle JJ, Tarride JE, Casciano R. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Managed Care Interface. 2000; 13: 88-94.

Casciano J, Doyle JJ, Amaya K, Kim R, Arikian S. Setting reimbursement policy with cost-effectiveness analysis for the treatment of patients with glioblastoma multiform. Managed Care & Cancer, 2000; 2(2): 16-22.

Casciano J, Arikian S, Tarride J-E, Doyle JJ, Casciano R. A pharmacoeconomic evaluation of major depressive disorder (Italy). Epidemiologia e Psichiatria Sociale, 1999; 8(3): 220-231.

Einarson TR, Arikian SR, Casciano J, Doyle JJ. Comparison of Extended-Release Venlafaxine, Selective Serotonin Reuptake Inhibitors, and Tricyclic Antidepressants in the Treatment of Depression: A Meta-Analysis of Randomized Controlled Trials. Clinical Therapeutics. Vol 21, No. 2, 1999.

Arikian SR, Einarson TR, Casciano JP, Doyle JJ. A health policy analysis of pharmacotherapy for major depressive disorder in Europe and the Americas. Value in Health. 1998; 1(1): 84.

Doyle JJ, Sinha N. Economics of ifosfamide-based chemotherapy in the outpatient setting. Cancer Mgmt. 1998; 3-4:18-24.

Shear NH, Einarson TR, Arikian SR, Doyle JJ, Van Assche D. Pharmacoeconomic analysis of topical treatments for tinea infections. Int J Dermatol. 1998; 37(1): 64-71.

Sinha N, Hainsworth JD, Einarson TR, Doyle JJ, Arikian SR, Lappas PT. A health-economic evaluation of paclitaxel and carboplatin versus vinorelbine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer. Value in Health. 1998; 1(1): 71.

Murad A, Andrade CA, Delfino C, Doyle JJ, Dezii CM, Sadana A, Sinha N. Pharmacoeconomic Evaluation of Tegafur-Uracil (UFT) vs Fluorouracil for the Management of Colorectal Cancer in Brazil and Argentina. Clinical Drug Investigators. 2, February 1997: 90-98.

McGuire W, Neugut AI, Arikian SA, Doyle JJ, Dezii CM. Analysis of the Cost-Effectiveness of Paclitaxel as Alternative Combination Therapy for Advanced Ovarian Cancer. Journal of Clinical Oncology. February 1997;15 (2), 640-645.

Murad A, de Andrade CA, Delfino C, Arikian SR, Doyle JJ, Sinha N. A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America. Oncology. 1997; 11(9 Suppl 10): 128-35.

Arikian SR, Einarson TR, Doyle JJ. Economic evaluation of treatments for eczema and atopic dermatitis. Care Management of Skin Disease. 1997; 23: 317-340.

Arikian, SR, Doyle JJ, Markison B. Medicine Joins the Information Highway. Medical Marketing and Media. February 1997.

Doyle JJ, Dezii CM, Sadana A. A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer. Semin Oncol. 1996 Dec;23(6 Suppl 13):51-60.

Doyle JJ, Casciano JP, Arikian SA, Mauskopf J, Paul JE, Full-Cost Determination of Different Level of Care in the Intensive Care Unit. Pharmacoeconomics. 1996; 10(4): 395-408.

Arikian SR, Mario GG, Doyle JJ. Building a computerized disease management operating system. Oncology. 1996; 10 (11 Suppl): 223-32.

Arikian SR, Suver J, Einarson T, Doyle JJ. Economic and Quality of Life Outcomes: The Four-Step Pharmacoeconomic Research Model. A Supplement to Oncology. 1995; 9: 33-36.

Arikian SR, Suver J, Doyle JJ, Sweeney SW, Hagan, M. Use of Anesthesia Selection in Controlling Surgery Costs in an HMO Hospital. Clinical Therapeutics. 1995; 17: 561-570.

Arikian SR, Einarson TR, Doyle JJ. Rank-Order Stability Analysis (ROSA): Testing Pharmacoeconomic Data. Medical Decision Making. 1995; 15: 367-372.

Einarson TR, Arikian SR, Doyle JJ, Sweeney SW. A Model to Evaluate the Cost-effectiveness of Oral Therapies in Major Depressive Disorder. Clinical Therapeutics. 1995; 17: 136-153.

Shear NH, Einarson TR, Arikian SR, Doyle JJ. Pharmacoeconomic Analysis of Topical Treatments for Tinea Infections. Pharmacoeconomics. 1995; 7: 251-26

Belani C, Einarson TR, Arikian SR, Doyle JJ. Cost-Effectiveness Analysis of Pleurodesis in the Management of Malignant Pleural Effusion. The Journal of Oncology Management. 1995; 4: 24-34.

Suver J, Arikian SR, Doyle JJ, Sweeney SW. A Multi-factorial Approach to Understanding the Total Economics of Anesthesia Selection. Health Care Management Review 1995; 20: 7-15.

Shear NH, Einarson TR, Arikian SR, Doyle JJ, van Assche D. Therapie von Tinea-Infektionen: Eine pharmacoeckookonomische Analyse der topischen Terapie in Osterreich, Deurschland und der Schweiz. Z. Allergy Med 1995; 71: 1055-1060.

Arikian SR, Einarson TR, Kobelt-Nguyen G, Schubert F and the Onychomycosis Study Group (including Doyle JJ). A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. British Journal of Dermatology (1994) 130 (Suppl. 43): 35-44.

White Papers & Trade Press

“FDA My Studies release is a major milestone with profound implications, say IQVIA.” OutsourcingPharma. December 2018

Real World Evidence: Advancing both clinical and commercial objectives. Pharmaceutial Commerce. December 2018

Value Frameworks. Pharmaceutical Commerce. May 2017

Value to outcomes (V2O) 2.0: Quintiles helping life science companies sense and respond to an increasingly evidence-based marketplace. Doyle JJ. March 2016

“Who defines value? Quintiles talks about changing the reimbursement landscape.” Doyle JJ. June 2016

Payer influence makes inroads in clinical research. Market access informing development planning and protocol design. The CenterWatch Monthly. Sax R and Doyle JJ. Dec 2016

Integrated asset development for optimizing value and outcomes White Paper. Doyle JJ and Connelly N. 2016

Value to outcomes (V2O): Quintiles helping life science companies sense and respond to an increasingly evidence-based marketplace. Doyle JJ. Dec 2015

Epidemiology Arising: A Pharma Exec Roundtable. Pharmaceutical Executive (cover article). Sept 2015

Pharmaceutical Commerce – Doyle JJ, Faulkner & Starzyk. Pharmaceutical Commerce. August 2015

Overcoming China’s Affordability Gap: Dramatic Change Creates Biopharma Industry Opportunities. Doyle JJ. Scrip Asia. June 2013

Innovation, Coverage and Costs. Pharmaceutical Executive. Washington Report. Wechsler J and Doyle JJ. June 2013.

Clinical and economic evidence thresholds for orphan drugs: Are requirements for favorable health technology assessment and reimbursement on the rise? Shih AY, Duong A, Tao C, Ransom JF, Spinner DS, White C, Doyle JJ, Faulkner EC. Value in Health. 2013 May;16(3):A108. doi: 10.1016/j.jval.2013.03.512. Epub 2013 May 3.

Cost-saving measures in reimbursement of orphan drugs under medicare prescription drug plans. Sepulveda B, Doyle JJ. Value in Health. 2013 May;16(3):A254. doi: 10.1016/j.jval.2013.03.1299. Epub 2013 May 3.

After the Cliff: Seizing a new future for a changed industry. Doyle JJ, McKemey A. White Paper. 2012 A CRO’s Role in Driving Development to Match Market Demands. Doyle JJ, Horowicz-Mehler N. PM360. Oct 2011

Vantage Point: Comparative Effectiveness Research. Doyle, JJ. MM&M. November 2011 An Integrated Approach to Biosimilar Development & Commercialization. Dahal D, Doyle JJ, Hecht J. Quintiles White Paper. 2011

Abstracts

Arikian SR, Suver J, Doyle JJ, Sweeney SW. The pathways study: an analysis of the net economic impact of anesthesia selection of the total cost of surgery: results of an economic clinical trial comparing propofol to thiopental/insoflurane. Program/Proceedings of the American Society of Hospital Pharmacists Annual Meeting, Dec 1994

Belani C, Einarson TR, Arikian SR, Doyle JJ. Cost-effectiveness analysis of available sclerosis agents used for pleurodesis in the management of malignant pleural effusion. Program/Proceedings of the American Society of Clinical Oncology, May 1995

Doyle JJ, Dhanani. Health economic evaluation of high dose therapy with CVB regimen in relapsed or refractory Hodgkin’s Disease. The IBMTR/ABMTR Annual Participants Meeting. 1997

Arikian SR, Casciano J, Doyle JJ. Pharmacoeconomics of major Depressive Disorders - Drug Information Association. London, UK; February 1998

Arikian SR, Einarson T, Casciano J, Doyle JJ. A health policy analysis of pharmacotherapy for major depressive disorder in Europe and the Americas. Paris, France; Oct 1998

Arikian SR, Doyle JJ, Closon M-C, Tarride J-E. A Health Economic Evaluation of HRT in Belgium. ISPOR, Cologne, Germany; Dec 1998

Arikian SR, Einarson T, Casciano J, Doyle JJ. The budget impact of pharmacotherapy selection for major depressive disorder: a multinational study. ISPOR. Cologne, Germany; Dec 1998

Arikian SR, Einarson T, Casciano J, Doyle JJ. The budget impact of pharmacotherapies for major depression. ASHP. Las Vegas, NV; Dec 1998

Doyle JJ, Arikian SR, Amsel A, Casciano R. A Cost comparison study of amlodipine & enalapril as treatment for hypertension in the United States. ISPOR. Edinburgh, Scotland; November 1999

Arikian, S.R., Doyle JJ. Portfolio valuation & brand economics. Barnette Portfolio Conference Philadelphia, PA. November 1999

Casciano R, Arikian SR, Casciano J, Doyle JJ. Estimating patient level efficacy rates using data expressed at the population level. International Conference on Health Policy Research. Santa Monica, CA; Dec 1999

Casciano R, Arikian SR, Tarride JE, Doyle JJ. A method for comparing disparate outcome measures in trials of urinary incontinence: controlled release oxybutynin versus tolterodine. ISPOR. Arlington, VA; May 1999

Arikian SR, Casciano R, Casciano J, Doyle JJ. Emerging therapeutic options for overactive bladder: the economics of medicare populations in managed care. AMCP. Minneapolis, MN; April-May 1999

Doyle JJ. and Evans S. Health economics in end stage glaucoma. End Stage Glaucoma Advisory Board Meeting. ARVO. Fort Lauderdale, Florida 2000

Flack JM, Doyle JJ, Casciano R, Arocho R, Casciano J, Gonzalez M. The health economic impact of failure to reach blood pressure goals. ASH New York, NY; May 2000

Arikian SR, Ciuryla V, Doyle JJ, Casciano J, Casciano R, Hvidsten K. A multinational pharmacoeconomic evaluation of the seven-valent pneumococcal conjugate vaccine. ISPOR. Arlington, VA; May 2000

Doyle JJ, Arikian SR, Casciano J, Casciano R, Baleeva J, Gonzalez M. A pharmacoeconomic evaluation of hormone replacement therapy in the United Kingdom and Belgium. ISPOR. Arlington, VA; May 2000

Casciano J, Arikian SR, Doyle JJ, Casciano R. A managed care validation program for a pharmacoeconomic model of major depression. ISPOR.Arlington, VA; May 2000

Arikian SR, Ciuryla V, Doyle JJ, Casciano J, Casciano R, Krishnaswamy R, Hvidsten K. A multi-national pharmacoeconomic evaluation of the pneumococcal conjugate vaccine – ESPID.Amsterdam, The Netherlands; May 2000

Arikian SR, Casciano J, Doyle JJ, Casciano R, Kim R. A pharmacoeconomic analysis of doxazosin for the treatment of hypertension in diabetic patients in Italy. ESH.Göteborg, Sweden; June 2000

Doyle JJ, Arikian SR, Casciano J, Casciano R, Gonzalez M, Kopp Z. A cost comparison study of amlodipine and enalapril in the treatment of hypertension in Europe. ISPOR Antwerp, Belgium; November 2000

Casciano J, Doyle JJ, Casciano R, Kopp Z, Arikian SR, Marchant N, Kim R. Cost-effectiveness of doxazosin in combination therapy for hypertension treatment in diabetic patients in the U.K. ISPOR. Antwerp, Belgium; November 2000

Doyle JJ, Arikian SR. A pharmacoeconomic evaluation of hormone replacement therapy in the United Kingdom and Belgium. FIGO. Washington, D.C.; 2000

Flack JM, Doyle JJ, Casciano R, Arocho R, Casciano J, Gonzalez M. The health economic impact of failure to reach blood pressure goals. ASH. New York, NY; 2000

Doyle JJ, White TJ, Tran MH, Casciano R, Stern L. Economic impact of aggressive lipid lowering with atorvastatin on early recurrent ischemic events in acute coronary syndromes. 36th Annual ASHP Mid-year Clinical Meeting and Exhibits; 2001

Neugut A, Vredenburgh J, Weisberg J, Berenson K, Casciano R, Doyle JJ, Amaya K.. Relative efficacy and cost-effectiveness analysis (CEA) of docetaxel versus paclitaxel in treatment of metastic breast cancer (MBC). American Society of Clinical Oncology; 2001

Walt JG, Doyle JJ, Jacobsen G, Lebovics G, Schiffman R. MD utility assessment among patients with dry eye disease. American Academy of Ophthalmology. New Orleans, LA; 2001

Neugut AI, Vredenburgh J, Weisberg J, Berenson K, Casciano R, Doyle J, Amaya K. Relative efficacy and cost-effectiveness analysis (CEA) of docetaxel versus paclitaxel in the treatment of metastatic breast cancer (MBC). Proceedings of ASCO 20:208b, #2581, 2001

Casciano J, Arikian S, Doyle JJ, et al. Economic analysis of therapies for onychomycosis of the toenails and fingernails. World Congress of Dermatology June 2002. Paris, France; 2002

Doyle JJ, Amaya K, Casciano J, Kotak S, Buchholz P, Walt J. A disease severity staging system for measuring the cost of glaucoma progression in Europe. ISPOR 2002 5th Annual European Congress. Rotterdam, The Netherlands; 2002

Lee PP, Budenz DL, Chen PP, et al, Doyle JJ. A multi-center, retrospective study of resource utilization associated with severity of disease in glaucoma. American Academy of Ophthalmology/Pan American Academy of Ophthalmology (AAO/PAOO) Joint Meeting 2002. Orlando, FL; 2002

Mills R, Bundenz D, Lee P, Nocker R, Walt J, Casciano J, Doyle JJ, Evans S. Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease by a novel six point system. Association for Research in Vision Ophthalmology (ARVO). Fortl Lauderdale, FL; 2002

Walt J, Doyle JJ, Casciano J, Evans S, Kotak S. The development of a severity staging system for economic of the progression of glaucoma. International Society for Pharmacoeconomic Outcomes and Research (ISPOR). Arlington, VA; 2002

Moul JW, Penson DF, Evans CP, Doyle JJ, Gandhi S, Lamerato L, Stern LS, Siegartel LR. Metastatic progression rates after initial treatment for prostate cancer: Data from a Midwestern health care system. Annual Meeting of the American Urological Association; 2003

Najib MM, Doyle JJ, Katz LM, Fastenau JM, Rosenblatt LC. Costs and epidemiology of myelosuppression in chemotherapy-treated metastatic breast cancer patients. Annual Meeting of the American Society of Hematology. San Diego, CA; 2003

Neugut AI, Moul JW, Penson DF, Evans CP, Doyle JJ, Gandhi S, Lamerato L, Siegartel LR, Stern, L.S. PSA progression rates after initial treatment for prostate cancer: Data from a Midwestern health care system. American Society of Clinical Oncology: Detroit, MI; 2003

Penson DF, Moul JW, Evans CP, Neugut A, Doyle JJ, Gandhi S, Lamerato L, Stern L, Siegartel LR. The economic burden of PSA progression in prostate cancer: Findings from a retrospective analysis of health plan data. Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; 2003

Traverso CE, Gandolfi SA, Kelly SP, et al., Doyle JJ. Estimation of resource utilization associated with glaucoma disease progression in a multinational retrospective study in Europe. Annual Meeting of the American Academy of Ophthalmology. Anaheim, CA; 2003

Dharmarajan T, Norkus E, Mody S, Najib MM, Siegartel LR, Doyle, JJ, Yektashenas, B, Woodman RC. Chronic anemia in community-dwelling older adults is associated with an increase in falls and hip fractures. Annual Meeting of the American Geriatrics Society. Las Vegas, NV; 2004

Katz LM, Stern LS, Fastenau JM, Piech CT, Doyle JJ. Trends in outcomes and charges of acute myeloid leukemia in the elderly: A cross-sectional analysis of the Nationwide Inpatient Sample from 1993 to 2001. Annual Meeting of the American Society of Hematology. San Diego, CA; 2004

Marcus P, Oppenheimer EA, Katz LM, Doyle JJ, Patel PA. Use of a nebulized inhaled corticosteroid among elderly patients. The Gerontological Society of America's 57th Annual Scientific Meeting. Washington, DC; 2004

Siegartel LR, Mody SH, Piech CT, Doyle JJ, Woodman RC. Epidemiology and health resource utilization of anemia in elderly non-dialysis chronic kidney disease patients. National Kidney Foundation Clinical Meetings. Chicago, IL; 2004

Williams RT, O'Connell W, Walt JG, Siegartel LR, Katz LJ, Doyle JJ. Resource utilization of end-stage glaucoma patients receiving low vision care: A US multi-site retrospective study. ISPOR 7th Annual European Congress. Hamburg, Germany; 2004

Danis M, Chalfin DB, Doyle JJ, Bergermann R, Katz LM, Siegartel LR, Stern, LS, Rapaport J, Levy MM. Development of model-based computer software for ICU resource allocation. Annual Congress of the Society of Critical Care Medicine. Phoenix, Arizona, January, 2005

Marcus P, Oppenheimer EA, Katz LM, Doyle JJ, Patel PA. Use of nebulized budesonide inhalation suspension among older adult and elderly patients: An assessment of outcomes. Southwest Allergy Forum: Combined Meeting on Allergy, Asthma and Immunology. Puerta Vallarta, Mexico; January 2005

Marcus P, Oppenheimer EA, Katz LM, Doyle JJ, Patel PA. Use of nebulized budesonide inhalation suspension among older adult and elderly patients: An assessment of outcomes. The Western Society of Allergy, Asthma and Immunology. Lanai, HI; January 2005

Bukstein DA, Murphy KR, Katz LM, McDermott L, Doyle JJ, Patel PA: Adherence with controller therapies and decreased asthma exacerbations in young children. American Thoracic Society International Conference, San Diego, CA, May, 2005

Buchholz P, Steeds C, Stern LS, Wiederkehr DP, Doyle JJ, Katz LM, Figueiredo FC: Utility assessment among patients with dry eye disease in the UK. ISPOR 8th Annual European Congress, Florence, Italy, November 8, 2005

Katz LM, Doyle JJ, Bergemann R, Siegartel LR, Stern LS, Chalfin D, Danis M, Rapoport J, Levy MM. Use of a Modified Recursive Partitioning and Amalgamation (RECPAM) Technique in Outcomes Research. International Society of Pharmacoeconomics and Outcomes Research. Florence, Italy. November 2005

Bucholz P, Steeds CS, Stern LS, Wiederkehr DP, Doyle JJ, Katz LM, Figueiredo FC. Utility assessment among patients with dry eye disease in the UK. International Society of Pharmacoeconomics and Outcomes Research. Florence, Italy. November 2005

Stern LS, Doyle JJ, Katz LM, Dolgitser M. Use of intranasal amphotericin B in chronic rhinsinusitis patients: A survey of US otolaryngologists. American College of Allergy, Asthma & Immunology 2005 Annual Meeting. Anaheim, CA; November 2005

Niederman MS, Chalfin DB, Stern LS, Doyle JJ, Katz LM. Clinical and outcomes in patients treated with flouroquinolone therapy in the intensive care unit. 40th ASHP Midyear Clinical Meeting and Exhibition. Las Vegas, NV; Dec 2005

Walt JG, Buchholz PM, Chiang TH, Stern LS, Doyle JJ. Characterization of end-stage glaucoma patients and use of low vision care services: A survey study. Vision 2005. London, England; 2005

Danis M, Chalfin DB, Doyle JJ, et al. Development of model-based computer software for ICU resource allocation. Annual Congress of the Society of Critical Care Medicine. Phoenix, AZ; 2005

Chalfin DB, Danis M, Rapoport J, Levy MM, Katz LM, Siegartel LR, Bergemann R, Stern L, Doyle JJ. Recursive Partitioning and Amalgamation (RECPAM) to predict ICU survival and length of stay. Annual Congress of the Society of Critical Care Medicine. Phoenix, AZ; 2005

Geiser DK, Williams RT, O’Connell W, Pasquale L, Walt JG, Siegartel LR, Katz LM, Wang L, Doyle JJ, Stern, LS. Resource utilization of end-stage glaucoma patients receiving visual rehabilitation care: A U.S. multisite retrospective study. American Academy of Ophthalmology 2005 Annual Meeting. Chicago, Illinois; Oct 2005

Doyle JJ, Neugut AI, McBride RB, Jacobson JS, Grann VR, Hershman DL. Radiation Therapy and Cardiac Toxicity in Breast Cancer Patients 65 Years and Older: A Population Based Study. San Antonio Breast Cancer Conference, New York, NY; Dec 2005

Doyle JJ, Neugut AI, Jacobson JJ, Gran VR, Hershman DL. Chemotherapy and Cardiotoxicity In Older Breast Cancer Patients: A Population Based Study. San Antonio Breast Cancer Conference. New York, NY; Dec 2005

M.A. Omar, JJ Doyle, L.S. Stern, L. Wang, L.M. Katz, K.H. Kahler. Budget Impact of Introducing Zoledronic Acid to the Formulary of a Managed Care Organization for the Treatment of Paget’s Disease of the Bone. The Paget Foundation. Fort Lauderdale, FL; January 2006

Bukstein DA, Murphy KR, Katz LM, McDermott L, Doyle JJ, Patel PA. Adherence with controller therapies and decreased asthma exacerbations in young children. The Western Society of Allergy, Asthma and Immunology. Lanai, HI; January 2006

Omar M, Stern L., Katz L.M., Doyle JJ, Dolgitser M., Kahler K.H. Extended Use Bisphosphonates in Paget’s Disease Patients. The Paget Foundation. Fort Lauderdale, FL; January 2006

Tsai J, Walt JG, Doyle JJ, Stern LS, Katz LM, Siegartel LR, Dolgitser M. Pharmacotherapy Compliance and Glaucoma Surgery in Patients with Primary Open-Angle Glaucoma. American Glaucoma Society. Charleston, SC; March 2006

Pasquale LR, Walt JG, Chiang TH, Katz LM, Stern LS, Doyle JJ, Dolgitser M. Healthcare Charges of Patients with Ocular Hypertension. American Glaucoma Society. Charleston, SC; March 2006

Lee PP, Walt JW, Doyle JJ, Stern LS, Katz LM, Siegartel LR. Association between IOP fluctuation and glaucoma progression. American Glaucoma Society. Charleston, SC; March 2006

Stern LS, Wiederkehr DP, Doyle JJ, Katz LM, Rajagopalan K. Association between atypical antipsychotic compliance and hospitalization and emergency department visits in patients with bipolar disorder. American Psychiatric Association Annual Meeting. Toronto, Canada. 2006

Doyle JJ, Stern LS, Dolgitser M, Katz LM, Omar MA, Kahler KH. Treatment patterns and resource utilization in patients with Paget’s disease treated with risedronate. International Society for Pharmacoeconomics and Outcomes Research. Philadelphia, PA; May 2006

Mannino DM, Shorr AF, Doyle JJ, Stern LS, Dolgitser M, Siegartel LR, Zilberberg MD. Prevalance of anemia in subjects with chronic obtrusive pulmonary disease. American Thoracic Society. San Diego, CA; May 2006

Shaheen NJ, Berenson KL, Doyle JJ, Brown KA. How Do Consumers Take “Over-the-Counter” Omeprazole? Digestive Disease Week. Los Angeles, CA; May 2006

Doyle JJ, Hershman DL, Neugut AI, Stern LS, Katz LM, Dolgitser M. Chemotherapy-related adverse events among breast cancer patients: A retrospective analysis of the SEER-Medicare database. American Society of Clinical Oncology, Atlanta, GA; June 2006

Mills RP, Budenz DL, Lee PP, Noecker RJ, Walt JG, Siegartel LR, Evans SJ, Doyle JJ. Categorizing the stage of glaucoma from pre-diagnosis to end stage disease. American Journal of Ophthalmology. 2006

Hauch O, Doyle JJ, Stern LS, Berenson K, Hendlish SK. Retrospective Study of Clopidogrel Use Among Patients With Acute Coronary Syndrome (ACS) Undergoing Coronary Artery Bypass Graft. ISPOR 9th Annual European Congress. Copenhagen, Denmark. Oct 2006

Traverso CE, Walt JG, Chiang TH, Stern LS, Doyle JJ, Hendlish SK, Dolgitser M. Effect of Intra-Ocular Pressure (IOP) Lowering Medication on Risk of Ocular Ischemic Events. American Academy of Ophthalmology. Las Vegas, NV. November 2006

Lee P, Levin LA, Walt JG, Chiang TH, Stern LS, Doyle JJ, Dolgitser M. Characteristics associated with increased healthcare charges of patients with primary open-angle glaucoma (POAG). American Academy of Ophthalmology. Las Vegas, NV. November 2006

Williams SA, Stern, LS, McMurray JJ, Dunlap ME, Michelson EL, Doyle JJ, Siegartel LR, Krukas M, Carlsson J. “A Pharmacoeconomic Evaluation Of The Effects Of Candesartan On Cardiovascular Hospitalizations In Patients With Chronic Heart Failure” [Abstract]. American Heart Association: Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington, DC, May 2006

Shorr AF, Stern LS, Raut MK, Rosenblatt LC, Chalfin DB, Hendlish SK, Doyle JJ, Zilberberg MD. Outcomes of transfusions in critically III patients on prolonged mechanical ventilation. The Society of Critical Care Medicine 36th Critical Care Congress. Orlando, FL. February 2007

Doyle JJ, Stern LS, Wiederkehr DP, Etschmaier MR, Sweet AC. Peripheral arterial disease in diabetic patients: A cost-effectiveness analysis comparing emerging magnetic resonance angiography with digital subtraction angiography. ISPOR 12th Annual International Meeting. Arlington, VA. May 2007

Brixner DI, Horowicz-Mehler N, Stern L, Doyle JJ, Dolgitser M, Hagan M. Contraceptive and Non-Contraceptive Benefits of the Levonorgestrel Intrauterine System (LNG-IUS) in a Vertically Integrated HMO (Henry Ford Health System. ISPOR 12th Annual International Meeting. Arlington, VA. May 2007

Casciano R, Doyle JJ, Kellner JD, Dolgitser M, Stern LS, Krukas MR, Fontaine L, Vicente C. Pharmacoeconomic evaluation of herd immunity conferred by seven-valent pneumococcal conjugate vaccine (Prevnar) in Canada based on Calgary region epidemiological data. ISPOR 12th Annual International Meeting. Arlington, VA. May 2007

Guo A, Doyle JJ, Stern L, Chen Y, Etschmaier M. A Pre-Post Time in Motion Methodology to Examine Product Wastage Reduction: Pilot Results in Magnetic Resonance Contrast Media Pharmacy Bulk Pack. ISPOR 12th Annual International Meeting. Arlington, VA. May 2007

Tsai JC, Lee J, Williams K, Walt JG, Doyle JJ, Stern LS, Dolgitser M. The Impact of Pharmacotherapy Compliance on Healthcare Charges in Patients with Primary Open-Angle Glaucoma. ISPOR 12th Annual International Meeting. Arlington, VA. May 2007

Walt JG, Chiang TH, Doyle JJ, Berenson KL. Cost of Standard Care Treatment in Patients with Progression of Primary Open Angle Glaucoma. ISPOR 12th Annual International Meeting. Arlington, VA. May 2007

Walt JG, Chiang TH, Stern L, Doyle JJ, Berenson KL. Costs and Resource Utilization among Patients with Progression of Primary Open Angle Glaucoma. AMCP 2007 Educational Conference. Boston, Massachusetts. Oct 2007

Strutton DR, Casciano R, Stern L, Doyle JJ, Berenson KL. A Multinational Pharmacoeconomic Evaluation of Direct and Indirect Immunity Conferred by the Seven-Valent Pneumococcal Conjugate Vaccine (PCV7). ISPOR 10th Annual European Congress. Dublin, Ireland. Oct 2007

Kalpas E, Doyle JJ. Cost-Effectiveness of Targeted Oncology Therapies: A Systematic Literature Review. ISPOR 10th Annual European Congress. Dublin, Ireland. Oct 2007

Krukas M, Berenson K, Hendlish S, Doyle JJ. Retrospective Measurement of Uncoded Disease Outcomes in a Claims Database. ISPOR 10th Annual European Congress. Dublin, Ireland. Oct 2007

Walt JG, Chiang TH, Stern L, Doyle JJ, Berenson K. Cost of Standard Care Treatment in the United Kingdom Among Patients with Progression of Primary Open Angle Glaucoma. ISPOR 10th Annual European Congress. Dublin, Ireland. Oct 2007

Walt JG, Dolgister M, Doyle JJ, Stern LS, Widerkehr D, Malangone E, Pasquale LR, Healthcare charges in patients who transition from OHTN to POAG. American Glaucoma Society 2008 Annual Meeting. Washginton, DC. March 2008

Dolgitser M, Walt J, Doyle JJ, Stern L, Wiederkehr D, Malangone E, Pasquale L. Healthcare charges in patients who undergo laser trabeculoplasty. 2008 Association for Research in Vision and Ophthalmology Annual Meeting, Ft. Lauderdale, FL, May 2008

Sepulveda B, Horowicz-Mehler N, Doyle JJ. The Effects of NICE HTAs on Prescription Volume, Average Retail Price, and Average Out-of-Pocket Costs of Drugs Deemed Medically Necessary for Medicare Part D Reimbursement in the US. ISPOR 11th European Congress. Athens, Greece. November 2008

Horowicz-Mehler N, Sepulveda B, Doyle JJ. Medicare Part D’s Market Impact on Utilization, Average Retail Price, and Out-of-Pocket Spending for Oral Chemotherapeutics and a Comparative Market Basket of Drugs. ISPOR 11th European Congress. Athens, Greece. November 2008

White C, Sepulveda, B, Doyle JJ. Medicare Part D’s Effect on Prescribing Volume: Average Monthly Utilization of Selected High Use Drugs in the Protected Classes, By Different Specialties. ISPOR 11th European Congress. Athens, Greece. November 2008

Doyle, JJ. Orphan Drugs Market Access in the United States. ISPOR 14th Annual International Meeting. Orlando, Florida. May 2009

Doyle, JJ. The Effects of Nice HTAS on Drug Prescribing and Expenditures in the United States. ISPOR 14th Annual International Meeting. Orlando, Florida. May 2009

Doyle, JJ White C, Sepulveda B. The Impact of Medicare part D (MMA-D) on Total Prescriptions (TRX) and Out-of-Pocket Costs (OPC) of Medically Necessary Drug Classes. DIA Annual Meeting. San Diego, California. June 2009

White C, Doyle JJ, Sepulveda B. Medicare Part D (MMA-D) Spillover Effect: An Analysis of Out-of-Pocket Costs (OPC) in Commercial Insurance Plans Following MMA-D Implementation. DIA Annual Meeting. San Diego, California. June 2009

White C, Doyle JJ, Sepulveda B. The Relationship Between Drug Utilization and Out-of-pocket Expenses for Oral Anti-neoplastics compared to a market basket of commonly used drugs. ISPOR Annual European Meeting. Paris, France. Oct 2009

Baumgartner J, Doyle JJ, Bell J. HPV Vaccine Coverage and Adoption Across the United States. ISPOR 15th Annual International Meeting. Atlanta, GA. May 2010

Doyle JJ. The Prescription Drug Burden for US Adults between the Ages of 55 to 64. ISPOR 15th Annual International Meeting. Atlanta, GA. May 2010

Wiederkehr D, Doyle JJ, Nichols E. Time-Release Launch in Relation to Generic Launch: Cases. ISPOR 15th Annual International Meeting. Atlanta, GA. May 2010

Gemmen E, Nagal M, Smith B, Garvert W, Doyle JJ. Assessment of the Clinical and Economic Impact of Air Leaks During Post-Operative Pulmonary Surgery. ISPOR 15th Annual International Meeting. Atlanta, GA. May 2010

Horowicz-Mehler N, Sepulveda B, White C, Doyle JJ. The Impact of the FDA’s Risk Evaluation and Mitigation Strategies (REMS) Initiative on Prescription Pattern for Drugs Approved Under the REMS Program and Relevant Non-REMS Competitors. ISPOR 15th Annual International Meeting. Atlanta, GA. May 2010

Baumgartner J, Doyle JJ, Bell J. Meningitis Vaccine Coverage and Adoption Across the United States. ISPOR 15th Annual International Meeting. Atlanta, GA. May 2010

Doyle JJ. Economic Burden of Venous Thromboembolism in US Hospitals. ISPOR 15th Annual International Meeting. Atlanta, GA. May 2010

Horowicz-Mehler N, Doyle JJ. The Benefits and Risks of using Observational Research to Measure CER. Academy Health Annual Research Meeting. Boston, MA. June 2010

Sheng J, Malhotra M, Vincent L, Hoschander S, Doyle JJ. A Novel Method for Combining Three Current Estimation Approaches to Pharmaceutical Pricing. ISPOR 13th Annual European Congress. Prague, Czech Republic. November, 2010

Gemmen E, Doyle JJ, Smith BF, Garvert W, Proach J, Long J, Nagel MP. Assessment of the Clinical and Economic Impact of Air Leaks During Post-Operative Pulmonary Surgery Using the Medicare Population. ISPOR 13th Annual European Congress. Prague, Czech Republic. November, 2010

Nichols E, Wiederkehr DP, Doyle JJ. Primary Prevention as Expanded Indication to Mitigate Competition: A Case Study. ISPOR 13th Annual European Congress. Prague, Czech Republic. November, 2010

Sepulveda B, Doyle JJ. The Effects of Nice Appraisals on Prescribing and Cost-Sharing Behavior in the US. ISPOR 13th Annual European Congress. Prague, Czech Republic. November, 2010

Nichols E, Wiederkehr DP, Doyle JJ. The Impact of Potential Pill Splitting on Generic and Branded Finasteride Uptake. ISPOR 13th Annual European Congress. Prague, Czech Republic. November, 2010

Guo, JJ., Pandey, S., Doyle JJ, Bian, B, Lis, Y, and Raisch, DW. "A Review of Quantitative Risk-Benefit Methodologies for Assessing Drug Safety and Efficacy-Report of the ISPOR Risk-Benefit Management Working Group." Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research. April, 2010

Sepulveda B, Doyle JJ, White C. The Impact of Medicare Part D on Medically Necessary Drugs. ISPOR 16th Annual International Meeting. Baltimore, MD. May 2011

Sepulveda B, Doyle JJ. The Potential Value of the 2014 Medicaid Expansion. ISPOR 16th Annual International Meeting. Baltimore, MD. May 2011

Sepulveda B, Doyle JJ. Orphan Drug Access in Medicine Plans in the United States. ISPOR 14th Annual European Congress. Madrid, Spain. November, 2011

Cummins G, Britton K, Doyle JJ. Landmark CER Study Methods Review. ISPOR 14th Annual European Congress. Madrid, Spain. November, 2011

Cummins G, Duong A, Doyle JJ. Multi-Stakeholder Survey of Comparative Effectiveness Research Perceptions. ISPOR 14th Annual European Congress. Madrid, Spain. November, 2011

Cox T, Gemmen E, Nixon M, Doyle JJ, Burgess A, Kamble H. Sample Size Estimation for Prospective Observational Studies. ISPOR 14th Annual European Congress. Madrid, Spain. November, 2011

Halim N, Doyle JJ. Comparative Effectiveness Research (CER): A Tool for Driving Payment and Delivery Reform Case Studies. DIA Annual Meeting. Philadelphia, Pennsylvania. June 2012

Doyle, JJ. Environment for Health Care Decision Making: Role of CER, Evidence-Based Medicine, Quality and Value. DIA Annual Meeting. Philadelphia, Pennsylvania. June 2012

Doyle, JJ. Market Access for Orphan Drugs in the US. DIA Annual Meeting. Philadelphia, Pennsylvania. June 2012

Doyle, JJ. The Effects of NICE Technology Assessments on Prescribing and Cost-sharing Behavior in the US. DIA Annual Meeting. Philadelphia, Pennsylvania. June 2012

Doyle, JJ. Public Health Innovation: Biopharmaceuticals Lost in Translation? ISPOR 17th Annual International Meeting. Washington, DC. June, 2012

Doyle, JJ. The Impact of Comparative Effectiveness Research on Drug Utilization in the United States. ISPOR 17th Annual International Meeting. Washington, DC. June, 2012

Feelders RA, Forsythe A, Stemmer V, Cummins G, Gourgiotis L, Doyle, JJ. Burden of Cushing’s Disease – A Retrospective Chart Audit. ENEA Conference. Vienna, Austria. Sept 2012

Badia X, Forsythe A, Cummins G, Roset M, Doyle JJ. Long-term Survival in Treated Patients with Cushing’s Disease: Results of a Markov Decision Model. ENEA Conference. Vienna, Austria. Sept 2012

Spinner DS, Ransom JF, Culp JL, White C, Doyle JJ. Point-of-Care Diagnostic Test Reimbursement and Market Access: Lessons From a Survey of Global Health Technology Assessments. ISPOR 15th Annual European Congress. Berlin, Germany. November 2012

Spinner DS; Ransom JF; Culp; Tao C; Casazza C; White C; Doyle JJ, Faulkner E. Reimbursement and Market Access of Imaging Diagnostics Applications: Lessons from a Survey of Global Health Technology Assessments. International Society for Pharmacoeconomics and Outcomes Research. 18th Annual International Meeting. New Orleans, LA. May 2013

Sepulveda B; Doyle JJ. COST-SAVING MEASURES IN REIMBURSEMENT OF ORPHAN DRUGS UNDER MEDICARE PRESCRIPTION DRUG PLANS. ISPOR. 18th Annual International Meeting. New Orleans, LA. May 2013

Hoschander S; Doyle JJ. A SYSTEMS-THINKING APPROACH FOR THE HEALTHCARE INDUSTRY: STRATEGIES AND INSIGHTS FOR BIOPHARMA, PAYERS AND PROVIDERS. International Society for Pharmacoeconomics and Outcomes Research. 16th Annual European Congress Meeting. Dublin, Ireland. November 2013

Chawla AS; Spinner DS; Ransom JF; Doyle JJ; Faulkner E. MARKET ACCESS OF IMPLANTABLE MEDICAL DEVICES: EVIDENTIARY REQUIREMENTS ACROSS GLOBAL MARKETS. International Society for Pharmacoeconomics and Outcomes Research. 16th Annual European Congress Meeting. Dublin, Ireland. November 2013

Spinner DS; Ransom JF; Culp JL; Chawla AS; Doyle JJ; Faulkner E. HEALTH TECHNOLOGY ASSESSMENT OF COMPANION DIAGNOSTIC BIOMARKERS AS GATEKEEPERS FOR PERSONALIZED MEDICINE MARKET ACCESS. ISPOR. 16th Annual European Congress Meeting. Dublin, Ireland. November 2013

Hoschander S, Doyle JJ, Istas A. A Systems-thinking Approach for the Healthcare Industry. ISPOR 19th Annual International Meeting. Palais des Congrès de Montréal. May, 2014

Horowicz-Mehler N, Tao C, Faulkner EC, Doyle JJ. AN ANALYSIS OF REAL WORLD DATA TRENDS IN GLOBAL HTA MARKETS. ISPOR 19th Annual International Meeting. Palais des Congrès de Montréal. May, 2014

Hoschander S, Doyle JJ, Istas A, Faulkner EC. PERSONALIZED DRUG DEVELOPMENT: STRATEGIC AND OPERATIONAL INSIGHTS FOR BIOPHARMA, PAYERS AND PROVIDERS FROM A LARGE SURVEY OF US AND EU DECISION MAKERS. ISPOR 19th Annual International Meeting. Palais des Congrès de Montréal. May, 2014

Faulkner EC, Spinner DS, Ransom JF, Crooks PD, Paul A, Chawla AS, Doyle JJ, Shaw WH, Fitzgerald JT. Next Generation Sequencing Technology: Health TechNOlogy Assessment, Market Access Trends and Potential Impacts on the Future of Companion Diagnostic Testing. ISPOR 17th Annual European Congress. Amsterdam, The Netherlands. November 2014

Culp JL, Connelly NM, Kristopik JL, Doyle JJ. Understanding Trends in Ophthalmologist Patient Selection and Care Based on Patterns of Billing. ISPOR 17th Annual European Congress. Amsterdam, The Netherlands. November 2014

Morawski, JH, Spinner, P, Doyle, JJ, Faulkner, EC, Ranson, JF. Reimbursement Trends and Evidence Requirements for Ultra-Orphan Disease Therapies Across Europe: Optimising Market Access in Increasingly Challenging Markets. ISPOR 17th Annual European Congress. Amsterdam, The Netherlands. November 2014

Paul, A., Morawski, JH, Spinner, DS, Doyle, JJ, Faulkner, EC, Ransom, JF.Global HTA Assessments of Ultra-Orphan Products: A Case Study of Eculizumab (Soliris) and Iduronate-2-Sulfatase (Elaprase). ISPOR 17th Annual European Congress. Amsterdam, The Netherlands. November 2014

Chawla AS, Acs A, Tao CY, Faulkner EC, Doyle JJ. Market Access of Implantable Medical Devices – Part II: Decision Drivers Across Global Markets. ISPOR 17th Annual European Congress. Amsterdam, The Netherlands. November 2014

Doyle JJ, White C, Chawla V, Hawryluk E. Is value truly in the eyes of the beholder? Analyzing the heterogeneity of outputs from ASCO, NCCN, and drugabacus oncology value frameworks and exploring implications for cancer drug development. ISPOR 17th Annual European Congress. Amsterdam, The Netherlands. November 2014

Chawla AS, Sethi T, Horowicz-Mehler N, Faulkner EC, Doyle JJ. Companion devices: Transformative mobile health technology towards improved patient care delivery. ISPOR 20th Annual International Meeting, Philadelphia, PA. May 2015

Chawla AS, Wood B, Myrick S, Chawla V, Doyle, JJ. Sensitivity of Clinical Endpoints in the ASCO Oncology Value Framework and Implications for Clinical Trial Design. ISPOR 21st Annual International Meeting, Washington, D.C. May 2016

Denysyk L, Doyle J, Sood R. A DIAGNOSTIC FRAMEWORK TO EVALUATE REAL-WORLD DATA SOURCES FOR REAL-WORLD EVIDENCE GENERATION. ISPOR Europe 2018, Barcelona, Spain. November 2018.

Invited Presentations

The Role of the Pharmaceutical Industry in Value-based Healthcare. Swansea University Value-based Healthcare Executive Education (virtual) program. Swansea, UK Sept 2020

Applying Real-World Data and Advanced Analytics in Value-based Healthcare. Doyle JJ The Multi-Stakeholder Commercial Model Summit. Boston, MA. Nov 2019

The Art of the Possible: Using Real World Evidence for Regulatory Support. Dreyer N and Doyle JJ. Astellas RWE Symposium. Chicago, IL. Nov 2017

Examining the Impact of Real-World Evidence on Medical Product Development: A Workshop Series. Aligning incentives in RWE: The CRO Perspective. Doyle JJ. National Academy of Sciences, Engineering & Medicine. Sept 2017

Challenges faced by regenerative medicine companies at demonstrating value to healthcare stakeholders. Doyle JJ. The New York Pharma Forum. Feb 2016

Connecting Insights from Pipeline to Portfolio to Population Health. Welcome Address and Keynote Presentation: Integrate evidence earlier – Using evidence to fuel smarter clinical development and value generation. Doyle JJ. Proventa Innovation Spotlight Session. Boston, MA. November 2016

Oncology Drug Development: The Disease, the Drug and the Costs. Value to Outcomes (V20) in Oncology Drug Development. Doyle JJ. The New Jersey Chapter of the American Statistical Association (ASA). 37th Annual Spring Symposium. Piscataway, NJ. June 2016

Trends and Innovations in Clinical Trial Statistics. Big Data and Analytics. Faries D, Lipkovich I, Doyle JJ. The North Carolina Chapter of the American Statistical Association (ASA). Durham, NC. May 2016

The Future of Value-based Contracting (keynote address). Doyle JJ. Merck Serono Global Market Access Summit. Boston, MA. Dec 2015

The value of regenerative medicine. Doyle JJ. . RegenMed Investor Day. New York, NY. March 2015.

Beyond RCTs; Exploring Biopharmaceutical Value and Outcomes Using Epidemiologic Approaches. Doyle, JJ, Aviles-Sanchez, L., Van staa, T. Sponsors: Columbia University Epidemiology & Unversite Paris Descartes. New York, NY. February 2015

Don’t Forget About the Patient! Listening to Patients Involving Them in Research. Doyle, JJ. International Society for Pharmacoeconomics and Outcomes Research. 18th Annual International Meeting. New Orleans, LA. May 2013.

Value Proposition and Evidence Optimization Strategy of Biosimilar Commercialization. Doyle, JJ. 12th Annual Biosimilars Americas. Boston, MA. April 2013. Drugs: Exclusivity under Challenge. Doyle, JJ, Landmon, CA, Nicholas, JM. The Food and Drug Law Institute (FDLI), Washington D.C. April 2013.

Comparative Effectiveness and Its Potential for Increased Quality and Efficiency. Frizzera C, Gottlieb S, Doyle JJ. American Health Lawyers Association (AHLA) and the Food and Drug Law Institute (FDLI) - The Intersecting Worlds of Drug, Device, Biologics and Health Law. Washington, DC. May 2012

Rare No More: The Possibilities of Rare Disease Research. Doyle, JJ, Kesselheim A, Meeker D, Long G. PhRMA Annual Meeting. Boston, MA. April 2012

You Ask, They Answer: How Comparative Effectiveness Research May Impact Drug Pipelines, Innovation and Patient Care—Can Innovation Survive CER? Doyle, JJ. Partnerships in Clinical Trials. Orlando, FL. March 2012

Reinventing Biopharma: Strategies for an Evolving Marketplace Patient Centric Drug Development. Doyle JJ. Economist Intelligence Unit. New York, NY. Dec 2011

How to Reward Innovation and Value in Comparative Effectiveness Research. Doyle JJ. The National Comparative Effectiveness Research Summit. Washington, D.C. Oct 2011

Comparative Effectiveness Research: Why is it different and how it impacts drug development and access to patients. Doyle JJ and Ratner R. Sanofi Visiting Professor Series. June 2011

Effect of Comparative Effectiveness Research on Drug Development Innovation: a 360° Appraisal and Summary Discussion. Doyle, JJ. Basler Biometric Section Seminar. Basel, Switzerland. May 2011

Regulation and Reimbursement in the New Washington.Gotlieb S, Doyle JJ, Brown L, Faulkner E. CED's Biotech/Life Science 2011 conference. Raleigh, NC. February 2011.

Let’s Make a Deal: Breaking Out of Organizational Silos – Bridging the Gap from Clinical Development to Commercialization. Doyle, JJ. 19th Annual Partnerships in Clinical Trials. Orlando, FL. April 2010

Lessons Learned: Applying Global Trends to Domestic Pricing Strategies. Doyle JJ, Malhotra, M. Center for Business Intelligence 3rd Annual Bio/Pharmaceutical and Medical Device Forum on Effective Product Pricing and Modeling Strategies. Princeton, NJ. April 2010

New Business Models for the Changing Commercial Landscape. Doyle JJ and Lennertz J. BayBio Annual Meeting. South San Francisco, CA. April 2008.

Panel Moderator & Panelist Engagements

The Future of Value. The Ochsner Value Summit. New Orleans, LA (virtual) Nov 2020

Pharmaceutical Industry Perspectives on Cancer Care. 10th Association for Value-Based Cancer Care Summit. New York, NY (virtual). Oct 2020

Gene Therapy Shared Value. 8th Annual Reimbursement & Access Congress. Aug 2020.

Gene Therapy Shared Value. The Basel Biometric Society. Basel, CH. June 2020.

Gene Therapy Shared Value. American Society of Gene & Cell Therapy. May 2020.

Breaking Down Barriers and Driving Innovation in our Healthcare System. Columbia Business School Healthcare Conference. New York, NY. Mar 2020.

Pharma and the Opportunities Ahead for New Innovative Value-Based Contracting Methodologies. Assoc Value-Based Cancer Care. Oct 2019

Real-World Noise, Trends, Realities, and Implications on the Road to Value-Based Contracting in Cancer Care. Assoc Value-Based Cancer Care. Oct 2019

Understand Payers’ Goals in Contract Arrangements to Ensure a Successful Value-Based Relationship. Value-based Healthcare Conference. Washington DC. Oct 2019

The Empowered Patient: Impact of Digital and “Big Data”. BioNJ C-Suite Summit. Bridgewater, NJ. Oct 2018

Navigating acceptance, uptake, and affordability across the lifecycle. The Cell & Gene Meeting on the Mesa. La Jolla, CA. Oct 2018

Digital Technologies for 21st Century Healthcare: A Roundtable Discussion. The British Consulate General Residence. New York, NY. Sept. 2018

Informing Clinical Design with an Eye Towards Commercial Success. Cell & Gene Meeting on the Mesa. La Jolla, CA. Oct 2017

Merck Center for Outcomes Research Primary Care Global Payer Advisory Panel. Boston, MA. May 2017

Redesigning a System: The Health Equity Factor. At What Cost? Drug Pricing and Access. Columbia University Mailman School of Public Health Healthcare Policy & Management Conference. New York, NY. April 2017

The Impact of a New Healthcare Model: What Do Payers Think of Gene Therapies? Cell & Gene Meeting on the Mesa. La Jolla, CA. Sept 2016

Evidence Now! Epidemiology Arising: A Pharma Exec Roundtable. Pharmaceutical Executive (Reported as cover article in Sept 2015 issue). New York, NY. Sept 2015

Pfizer Latin America Rare Disease Patient Advocacy Summit. Buenos Aires, Argentina. May 2015

3rd Annual Regenmed Investor Day. Alliance Regenerative Medicine. New York, NY. March 2015.

Research & Development and Alliances Panel Discussion. Life Sciences Markets Symposium - The Power of Partnerships. New York, NY. July 2014

Research & Development and Alliances Panel Discussion. Life Sciences Markets Symposium . New York, NY. July 2013

Pfizer Specialty Pharmaceutical Market Access Advisory Panel. Panel on Global Market Access Priorities. Berlin, Germany. November 2012

Panel on Private Reimbursement Issues. NCBIO 2012 Annual Meeting. Research Triangle Park, NC. Oct 2012

After the Cliff: Seizing a New Future for a Changed Industry. Quintiles Executive Vision Forum. Princeton, NJ. Oct 2012

Podcasts & Webinars

Real-World Data Collection for Cell & Gene Therapies. FasterCures, a Center of the Milken Institute Webinar. Marks P, Nichols G, Doyle JJ. September 2020.

Bold Voices: Dr. John Doyle, Global Healthcare Innovation Lead at Pfizer, sat down with Dr. Andrew Lo, Professor at the MIT Sloan School of Management and director of MIT’s Laboratory for Financial Engineering, to discuss innovative solutions to address affordability and increase patient access to breakthrough medicines. https://lnkd.in/e4kUh3M. Doyle JJ, Lo A. Sept 2019.

Value-based Healthcare. Vital Transformation Podcast. Doyle JJ. May 2019.

Rethinking Evidence Spend Podcast. Doyle JJ. IQVIA AccessPoint. Dec 2017

Real-World Evidence for Emerging Biopharma Webinar. Dreyer, N and Doyle JJ. Dec 2017

Value-Based Health Care for Patients, Providers & Payers Webinar. Doyle J.J (Moderator), Daniel R, Goodman C, Balch A, AMCP Foundation Research Symposium. November 2017

Real-world Evidence Optimization. Doyle JJ. Quintiles Webinar. Sept 2016

Patient-Centered outcomes Research Institute (PCORI) Preliminary Draft Methodology Report. Leavy M, Graf J, Doyle JJ. Quintiles-Outcome Podcast. July 2012

“Begin with the End in Mind”: Selecting the best approach for ‘real world’ evidence generation. Doyle, JJ. The Center for Business Intelligence Webinar. June 2011

Overcoming Global Marketing and Regulatory Challenges. Doyle JJ, Garabedian G. Pharmaceutical Executive Podcast. March 2009

Caveney E, Pritchett EL, Doyle JJ, Parentesis G. Recent FDA Guidelines in Type II Diabetes. Pharmaceutical Executive Webcast. May 2009

Using Patient Adherence Program to Prove the Value of your Brands for Today’s Payor Marketplace.Culp C, Chalfin D, Doyle JJ. Sinopoli J. Pharmaceutical Executive Webcast. January 2009

A New Gold Standard for Pricing. Doyle JJ. Envisage Podcast. March 2008

Prior Experience

Vice President, Global Healthcare Innovation Lead, Pfizer, 2019 – 2021

Senior Vice President & General Manager, Real-World Enterprise Solutions, IQVIA, 2016 – 2019

Senior Vice President & Managing Director, Value & Outcomes Center of Excellence, Quintiles, 2014 – 2016

Senior Vice President & Managing Director, Global Market Access, Quintiles, 2007 – 2014

President & Chief Operating Officer, Analytica International, Inc., 1997 - 2007

Associate Director, Health Economics, Bristol-Myers Squibb Company, 1995 – 1997

Senior Manager & Research Scientist, Health Economics Research, Inc., 1993 – 1995

Academic Appointments

Adjunct, Assistant Professor, Epidemiology, Columbia University, Mailman School of Public Health, 2005 – Present

Adjunct, Assistant Professor, Department of Health Policy and Management, Columbia University, Mailman School of Public Health, 2005–2007

Professional Affiliations

Alliance for Regenerative Medicine

International Society for Pharmacoeconomics & Outcomes Research

Additional Information

Peer Reviewer

Pharmacoepidemiology & Drug Safety

Transactions of the Royal Society of Tropical Medicine and Hygiene

Knowledge

News & Events

CREDENTIALS & PROFESSIONAL HONORS

  • Dr.P.H., Epidemiology, Columbia University, 2005
  • M.P.H., Epidemiology, Columbia University, 1998
  • B.Sc., Business Management and Applied Economics, Cornell University, 1992
  • Dissertation Defended with Distinction, Columbia University Mailman School of Public Health